Breaks Categories: News

MondayJan 09, 2023 12:35 pm

NetworkNewsBreaks – HIVE Blockchain Technologies Ltd. (NASDAQ: HIVE) (TSX.V: HIVE) (FSE: HBFA) Issues December 2022 Production Update

HIVE Blockchain Technologies (NASDAQ: HIVE) (TSX.V: HIVE) (FSE: HBFA) today announced production figures from its global bitcoin (“BTC”) operations for the month of December 2022 and the calendar year 2022. The company reportedly produced 213.8 bitcoin in December, plus USD $3.15 million of income from its energy price hedging and grid balancing strategy. Additionally, HIVE produced crypto assets with a value of 4,752 bitcoin (based on daily average price of BTC) in 2022, which is an 18% increase from the prior year. “We are very happy to be producing over 213 bitcoin this month, while also earning over USD $3…

Continue Reading

MondayJan 09, 2023 12:11 pm

NetworkNewsBreaks – AmeriCann Inc. (ACAN) Announces Record Fiscal Year-End and Quarterly Results

AmeriCann (OTCQB: ACAN), a cannabis company that develops state-of-the-art cultivation, product manufacturing and distribution facilities, today released financial and operational results for its fiscal year and quarter ending September 2022. “Our focus on cost efficiency has produced some of the strongest adjusted operating EBITDA margins in the industry,” said CFO Ben Barton. “We look forward to investing the cash flow we are generating to further expand operations at the Massachusetts Cannabis Center and to produce even better financial results for shareholders.” To view the full press release, visit https://nnw.fm/YCYFA About AmeriCann Inc. AmeriCann is a cannabis company that develops cultivation,…

Continue Reading

MondayJan 09, 2023 11:56 am

NetworkNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Incorporates New Subsidiary to Capitalize on Drug Development Incentives in Australia

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, today announced the incorporation of a new subsidiary to capitalize on drug development incentives in Australia. The company also announced its expanded focus to investigate other products addressing acute medical needs due to substances of abuse such as alcohol, as well as the appointments of Dr. Jeremy Chataway, Dr.Ashwin Dhanda and Dr. Anh Lê to its scientific and clinical expert committee. “We are excited about the incorporation of FSD Pharma Australia, where…

Continue Reading

MondayJan 09, 2023 10:37 am

NetworkNewsBreaks — MetAlert Inc. (MLRT) Featured in Ludlow Research Analyst Brief

MetAlert (OTC: MLRT), a pioneer in location-sensitive, health-monitoring devices and wearable technology products for remote patient monitoring, spotlighted in a recent Q&A analyst report released by Ludlow Research. In the article, MLRT representations respond to questions, providing an overview of the company and discussing specific topics investors and shareholders might be interested in. The report delved into the company’s recent restructuring, name change and ticker symbol change, with the company stating that “we waited patiently to do this until we had a clean balance sheet and were prepared to take the company to the next level.” The report noted that…

Continue Reading

MondayJan 09, 2023 10:30 am

NetworkNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Releases Status Update on Clinical Development Programs

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), is discussing upcoming priorities and near-term milestones regarding the status of its two clinical programs aimed at addressing multiple mental health conditions: CYB003 and CYB004. Designed for the treatment of Major Depressive Disorder (“MDD”), CYB003 is currently in a phase 1/2a clinical trial. CYB003 is a deuterated psilocybin analog. CYBN anticipates releasing an interim readout from the trial by the end of February 2023, which will provide an initial understanding of the safety and pharmacokinetic (“PK”) profile of the substance in humans. This interim data will…

Continue Reading

MondayJan 09, 2023 10:10 am

NetworkNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Begins New Year by Trading on Upstream

Nutriband (NASDAQ: NTRB), a pioneer in the science of using novel transdermal solutions and other innovative technologies, has kicked off the new by becoming the first NASDAQ company to dual list digital shares on Upstream, a fully regulated global stock exchange for digital securities and NFTs. The company began trading on Upstream yesterday under the ticker symbol NTRB. According to the announcement, the dual listing is designed to provide Nutriband with access to a global, digital-first investor base; potential investors will be able to trade using USDC digital currency as well as credit, debit, PayPal and USD, which will unlock…

Continue Reading

FridayJan 06, 2023 11:37 am

NetworkNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) to Participate in Upcoming J.P. Morgan Healthcare Conference

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, has announced that key executives will be attending the 41st annual J.P. Morgan Healthcare Conference. Scheduled for Jan. 9–12, 2023, in San Francisco, California, the conference has become largest and most informative healthcare investment symposium in the industry. The event is known for gathering together global industry leaders with officials from emerging fast-growth companies along with innovative technology creators and members of the investment community. FSD Pharma director and CEO Dr. Lakshmi…

Continue Reading

FridayJan 06, 2023 11:15 am

NetworkNewsBreaks – Cepton Inc.’s (NASDAQ: CPTN) Vista-X120 Plus Featured in FreightWaves Article

Cepton (NASDAQ: CPTN), a Silicon Valley innovator of high-performance lidar solutions, was featured in a recent article published by FreightWaves. The piece, written by Jack Daleo and titled “Cepton unveils slimmed-down lidar solution,” discusses the Vista-X120 Plus, which offers easy integration at a height of 30 mm. “As the autonomous vehicle industry begins to gather steam, manufacturers of lidar — short for light detection and ranging — are trying to do more with less. Cepton (NASDAQ: CPTN), one of the few publicly traded lidar companies in the U.S., on Tuesday unveiled the Vista-X120 Plus, billed as ‘the world’s slimmest software…

Continue Reading

FridayJan 06, 2023 10:18 am

NetworkNewsBreaks – Reklaim Ltd. (TSX.V: MYID) (OTCQB: MYIDF), Snowflake Partner to Help Fill Gap in US Data Market

Reklaim (TSX.V: MYID) (OTCQB: MYIDF), a leader in privacy-compliant data, today announced its collaboration with Snowflake, the Data Cloud company, to offer two compliant data sets on Snowflake Marketplace. These include a data set of individual consumers who have explicitly opted-in to sharing their sensitive personal data (“SPI”) for marketing purposes, as well as a do-not-sell data set of consumers who have specifically opted out of having their data sold. “With the enforcement period of CCPA beginning in January of 2023, offering distinct consumer consent for SPI data and do-not-sell signals to companies looking to ensure their data remains compliant…

Continue Reading

FridayJan 06, 2023 10:11 am

NetworkNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Releases Study Results Indicating Inhaled COVID-19 Therapy Virtually Eliminated SARS-COV-2 Virus

BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotech company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, is reporting additional results from a preclinical in vivo proof-of-concept study. The study evaluated BVXV’s innovative inhaled nanosized antibody (“NanoAb”) COVID-19 therapy; results indicate that the presence of the SARS-COV-2 virus in the lungs of hamsters treated with BiondVax’s NanoAb was “virtually eliminated” and significantly less than the amount of virus detected in the placebo group. Specifically, hamsters infected with SARS-COV-2 that were treated with BiondVax’s inhaled anti-COVID-19 nanosized antibodies had more than 30 times…

Continue Reading